MicroRNA-93 regulates cyclin G2 expression and plays an oncogenic role in laryngeal squamous cell carcinoma

Xiao,Xiyan; Zhou,Liang; Cao,Pengyu; Gong,Hongli; Zhang,Yanping

doi:10.3892/ijo.2014.2704

MicroRNA-93 regulates cyclin G2 expression and plays an oncogenic role in laryngeal squamous cell carcinoma

Authors:
- Xiyan Xiao
- Liang Zhou
- Pengyu Cao
- Hongli Gong
- Yanping Zhang
View Affiliations

Affiliations: Department of Otolaryngology-Head and Neck Surgery, Fudan University Affiliated Eye, Ear, Nose and Throat Hospital, Shanghai 200031, P.R. China, Central Laboratory, Fudan University Affiliated Eye, Ear, Nose and Throat Hospital, Shanghai 200031, P.R. China
Published online on: October 10, 2014 https://doi.org/10.3892/ijo.2014.2704
Pages: 161-174

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

microRNA93 (miR-93) is expressed in the miR‑106b-25 cluster, located in intron 13 of the MCM7 gene. Our previous study found that miR-93 was significantly upregulated in laryngeal squamous cell carcinoma (LSCC), and cyclin G2 (CCNG2) was a potential target of miR-93 in LSCC. However, the possible functions and molecular mechanisms of miR-93 in LSCC remain unknown. In the present study, we show that the level of CCNG2 protein expression was significantly lower in LSCC cancer tissue than normal tissues. The level of CCNG2 was correlated with clinical stages, lymph node metastasis and histological grade. We further show that the expression level of miR-93 was inversely correlated with CCNG2 expression in clinical specimens. Furthermore, gain-of-function assays revealed that miR-93 promoted cell proliferation, decreased apoptosis rates, induced cell cycle arrest and promoted cell migration and invasion, whereas silencing of miR-93 attenuated these carcinogenic processes. In addition, overexpression of miR-93 in Hep-2 cells could reduce the mRNA and protein levels of CCNG2, whereas silencing of miR-93 in Hep-2 cells significantly increased CCNG2 expression. A luciferase assay verified that miR-93 could bind to the 3' untranslated region of CCNG2. Importantly, ectopic expression of CCNG2 in miR-93 cells rescued the effect of miR-93 on LSCC proliferation. Knockdown of CCNG2 promoted cell proliferation resembling that of miR-93 overexpression. These findings demonstrated that miR-93 promotes tumor growth by directly suppressing CCNG2. Taken together, these results suggested that this newly identified miR-93-CCNG2 axis may be involved in LSCC proliferation and progression. Our findings provide novel potential targets for LSCC therapy and prognosis.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, et al: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Marioni G, Marchese-Ragona R, Cartei G, et al: Current opinion in diagnosis and treatment of laryngeal carcinoma. Cancer Treat Rev. 32:504–515. 2006. View Article : Google Scholar : PubMed/NCBI
3	Talamini R, Bosetti C, La Vecchia C, et al: Combined effect of tobacco and alcohol on laryngeal cancer risk: a case-control study. Cancer Causes Control. 13:957–964. 2002. View Article : Google Scholar : PubMed/NCBI
4	Menach P, Oburra HO and Patel A: Cigarette smoking and alcohol ingestion as risk factors for laryngeal squamous cell carcinoma at Kenyatta National Hospital, Kenya. Clin Med Insights Ear Nose Throat. 5:17–24. 2012. View Article : Google Scholar : PubMed/NCBI
5	Mohamadian Roshan N, Jafarian A, Ayatollahi H, et al: Correlation of laryngeal squamous cell carcinoma and infections with either HHV-8 or HPV-16/18. Pathol Res Pract. 210:205–209. 2014.PubMed/NCBI
6	Hoffman HT, Porter K, Karnell LH, et al: Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope. 116(Suppl 111): 1–13. 2006. View Article : Google Scholar : PubMed/NCBI
7	Zhang B, Pan X, Cobb GP, et al: microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12. 2007. View Article : Google Scholar : PubMed/NCBI
8	Shah MY and Calin GA: MicroRNAs as therapeutic targets in human cancers. Wiley Interdiscip Rev RNA. 5:537–548. 2014. View Article : Google Scholar : PubMed/NCBI
9	Kong YW, Ferland-McCollough D, Jackson TJ, et al: microRNAs in cancer management. Lancet Oncol. 13:e249–258. 2012. View Article : Google Scholar : PubMed/NCBI
10	Calin GA, Sevignani C, Dumitru CD, et al: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
11	Yeung ML, Yasunaga J, Bennasser Y, et al: Roles for microRNAs, miR-93 and miR-130b, and tumor protein 53-induced nuclear protein 1 tumor suppressor in cell growth dysregulation by human T-cell lymphotrophic virus 1. Cancer Res. 68:8976–8985. 2008. View Article : Google Scholar : PubMed/NCBI
12	Du L, Schageman JJ, Subauste MC, et al: miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. Mol Cancer Res. 7:1234–1243. 2009. View Article : Google Scholar : PubMed/NCBI
13	Singh B, Ronghe AM, Chatterjee A, et al: MicroRNA-93 regulates NRF2 expression and is associated with breast carcinogenesis. Carcinogenesis. 34:1165–1172. 2013. View Article : Google Scholar : PubMed/NCBI
14	Fang L, Deng Z, Shatseva T, et al: MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-β8. Oncogene. 30:806–821. 2011. View Article : Google Scholar : PubMed/NCBI
15	Fang L, Du WW, Yang W, et al: MiR-93 enhances angiogenesis and metastasis by targeting LATS2. Cell Cycle. 11:4352–4365. 2012. View Article : Google Scholar : PubMed/NCBI
16	Fu X, Tian J, Zhang L, et al: Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett. 586:1279–1286. 2012. View Article : Google Scholar : PubMed/NCBI
17	Liu S, Patel SH, Ginestier C, et al: MicroRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells. PLoS Genet. 8:e10027512012. View Article : Google Scholar : PubMed/NCBI
18	Bennin DA, Don AS, Brake T, et al: Cyclin G2 associates with protein phosphatase 2A catalytic and regulatory B’ subunits in active complexes and induces nuclear aberrations and a G1/S phase cell cycle arrest. J Biol Chem. 277:27449–27467. 2002. View Article : Google Scholar
19	Burgering BM and Kops GJ: Cell cycle and death control: long live Forkheads. Trends Biochem Sci. 27:352–360. 2002. View Article : Google Scholar : PubMed/NCBI
20	Martínez-Gac L, Marqués M, García Z, et al: Control of cyclin G2 mRNA expression by forkhead transcription factors: novel mechanism for cell cycle control by phosphoinositide 3-kinase and forkhead. Mol Cell Biol. 24:2181–2189. 2004.PubMed/NCBI
21	Arachchige Don AS, Dallapiazza RF, Bennin DA, et al: Cyclin G2 is a centrosome-associated nucleocytoplasmic shuttling protein that influences microtubule stability and induces a p53-dependent cell cycle arrest. Exp Cell Res. 312:4181–4204. 2006.
22	Cao P, Zhou L, Zhang J, et al: Comprehensive expression profiling of microRNAs in laryngeal squamous cell carcinoma. Head Neck. 35:720–728. 2013. View Article : Google Scholar : PubMed/NCBI
23	Wang L, Wang Q, Li HL, et al: Expression of MiR200a, miR93, metastasis-related gene RECK and MMP2/MMP9 in human cervical carcinoma--relationship with prognosis. Asian Pac J Cancer Prev. 14:2113–2118. 2013. View Article : Google Scholar : PubMed/NCBI
24	Kim BH, Hong SW, Kim A, et al: Prognostic implications for high expression of oncogenic microRNAs in advanced gastric carcinoma. J Surg Oncol. 107:505–510. 2013. View Article : Google Scholar : PubMed/NCBI
25	Xu D, He XX, Chang Y, et al: Downregulation of MiR-93 expression reduces cell proliferation and clonogenicity of HepG2 cells. Hepatogastroenterology. 59:2367–2373. 2012.PubMed/NCBI
26	Chen L, Jiang M, Yuan W, et al: Prognostic value of miR-93 overexpression in resectable gastric adenocarcinomas. Acta Gastroenterol Belg. 75:22–27. 2012.PubMed/NCBI
27	Montanini L, Lasagna L, Barili V, et al: MicroRNA cloning and sequencing in osteosarcoma cell lines: differential role of miR-93. Cell Oncol (Dordr). 35:29–41. 2012. View Article : Google Scholar : PubMed/NCBI
28	Yu XF, Zou J, Bao ZJ, et al: miR-93 suppresses proliferation and colony formation of human colon cancer stem cells. World J Gastroenterol. 17:4711–4717. 2011. View Article : Google Scholar : PubMed/NCBI
29	Sun GG, Zhang J and Hu WN: CCNG2 expression is down-regulated in colorectal carcinoma and its clinical significance. Tumour Biol. 35:3339–3346. 2014. View Article : Google Scholar
30	Cui DW, Sun GG and Cheng YJ: Change in expression of cyclin G2 in kidney cancer cell and its significance. Tumour Biol. 35:3177–3183. 2014. View Article : Google Scholar : PubMed/NCBI
31	Chen JQ, Liu CJ, Wen HX, et al: Changes in the expression of cyclin G2 in esophageal cancer cell and its significance. Tumour Biol. 35:3355–3362. 2014. View Article : Google Scholar : PubMed/NCBI
32	Kim Y, Shintani S, Kohno Y, et al: Cyclin G2 dysregulation in human oral cancer. Cancer Res. 64:8980–8986. 2004. View Article : Google Scholar : PubMed/NCBI
33	Sun GG, Hu WN, Cui DW, et al: Decreased expression of CCNG2 is significantly linked to the malignant transformation of gastric carcinoma. Tumour Biol. 35:2631–2639. 2014. View Article : Google Scholar : PubMed/NCBI
34	Cui DW, Cheng YJ, Jing SW, et al: Effect of cyclin G2 on proliferative ability of prostate cancer PC-3 cell. Tumour Biol. 35:3017–3024. 2014. View Article : Google Scholar : PubMed/NCBI
35	Ito Y, Yoshida H, Uruno T, et al: Decreased expression of cyclin G2 is significantly linked to the malignant transformation of papillary carcinoma of the thyroid. Anticancer Res. 23:2335–2338. 2003.PubMed/NCBI
36	Jiao J, Qin Z, Li S, et al: Potential role of Notch1 signaling pathway in laryngeal squamous cell carcinoma cell line Hep-2 involving proliferation inhibition, cell cycle arrest, cell apoptosis, and cell migration. Oncol Rep. 22:815–823. 2009.PubMed/NCBI
37	Ren J, Zhu D, Liu M, et al: Downregulation of miR-21 modulates Ras expression to promote apoptosis and suppress invasion of Laryngeal squamous cell carcinoma. Eur J Cancer. 46:3409–3416. 2010. View Article : Google Scholar : PubMed/NCBI
38	Che XH, Chen H, Xu ZM, et al: 14-3-3epsilon contributes to tumour suppression in laryngeal carcinoma by affecting apoptosis and invasion. BMC Cancer. 10:3062010. View Article : Google Scholar : PubMed/NCBI
39	Tian L, Li M, Ge J, et al: MiR-203 is downregulated in laryngeal squamous cell carcinoma and can suppress proliferation and induce apoptosis of tumours. Tumour Biol. 35:5953–5963. 2014. View Article : Google Scholar : PubMed/NCBI
40	Horne MC, Goolsby GL, Donaldson KL, et al: Cyclin G1 and cyclin G2 comprise a new family of cyclins with contrasting tissue-specific and cell cycle-regulated expression. J Biol Chem. 271:6050–6061. 1996. View Article : Google Scholar : PubMed/NCBI
41	Horne MC, Donaldson KL, Goolsby GL, et al: Cyclin G2 is up-regulated during growth inhibition and B cell antigen receptor-mediated cell cycle arrest. J Biol Chem. 272:12650–12661. 1997. View Article : Google Scholar : PubMed/NCBI
42	Bates S, Rowan S and Vousden KH: Characterisation of human cyclin G1 and G2: DNA damage inducible genes. Oncogene. 13:1103–1109. 1996.PubMed/NCBI
43	Wang DH, Hu JR, Wang LY, et al: The apoptotic function analysis of p53, Apaf1, Caspase3 and Caspase7 during the spermatogenesis of the Chinese fire-bellied newt Cynops orientalis. PLoS One. 7:e399202012. View Article : Google Scholar : PubMed/NCBI
44	Johansson N, Ahonen M and Kähäri VM: Matrix metalloproteinases in tumor invasion. Cell Mol Life Sci. 57:5–15. 2000. View Article : Google Scholar
45	Fink K and Boratyński J: The role of metalloproteinases in modification of extracellular matrix in invasive tumor growth, metastasis and angiogenesis. Postepy Hig Med Dosw (Online). 66:609–628. 2012.(In Polish).